Testosterone Decline & TRT: The Evidence, Honestly

Testosterone is the hormone most men think they are running out of — and the one most aggressively marketed to them. Here is what the decline actually looks like, what replacement therapy actually delivers in randomized trials, and where the honest line sits between treatment and trend.

The Decline Is Real — and the Range Is Wide

The Massachusetts Male Aging Study followed men longitudinally and measured total testosterone falling at roughly one percent per year from the thirties onward; the European Male Aging Study put the figure closer to half a percent a year for total testosterone, with free testosterone falling faster as the binding protein SHBG climbs with age. Every cohort agrees on the direction: a slow slide, not a cliff. The part the marketing leaves out is the spread. In the European cohort of men aged forty to seventy-nine, only about two percent measured below the young-adult reference range — meaning the overwhelming majority of aging men, into their eighth decade, carry testosterone levels that would look normal on a twenty-five-year-old's chart. Age pushes the average down; it does not sentence any individual man to a particular number. Obesity, chronic illness, and medication effects account for much of the decline that is popularly blamed on the calendar alone.

Low T Is a Diagnosis, Not a Single Number

The Endocrine Society's definition of hypogonadism has two gates, and both must open: symptoms (low libido, erectile difficulty, fatigue, loss of muscle) and a total testosterone below the reference range on two separate morning measurements. The morning part matters because testosterone runs on a daily rhythm — highest in the early hours, drifting down through the day, so an afternoon draw can read low for no clinical reason. The two-measurement part matters because the hormone is pulsatile and skittish: a bad night's sleep, an illness, a period of heavy training or undereating, and opioids or glucocorticoids can each depress a reading transiently. One more subtlety the online test-kits skip: obesity lowers SHBG, so total testosterone can look borderline-low while the free fraction that tissues actually see is normal — which is exactly why a clinician computes free testosterone before concluding anything. If you want to see where this fits in a broader self-tracking routine, the blood-marker audit covers the practical side — but the diagnosis itself belongs to a clinician, not a spreadsheet.

The Overlap Problem: Symptoms That Aging Also Explains

Here is the uncomfortable truth about the "low T symptoms" checklist: it is nearly identical to the checklist for aging, poor sleep, depression, and an underused body. The symptom overlap is why labs are non-optional — and why symptom-first marketing converts so many tired men into customers before any blood has been drawn.

None of this means the symptoms are imaginary. It means they have many owners, and the cheapest explanation — too little sleep, too few weights, too much alcohol — deserves first crack at them.

What TRT Actually Delivers: The Trial Record

The modern benchmark is the Testosterone Trials (2016): seven coordinated randomized trials in 788 men aged sixty-five and older with low testosterone, treated for one year. The results set the honest expectation bar for the entire category. Sexual activity and desire improved modestly; mood improved only in the subgroup that started depressed; the vitality trial's primary endpoint — fatigue — was not met; physical function improved in only one of the three trials that tested it; anemia corrected in roughly half of anemic men; and spine and hip bone density rose about three percent, with no fracture data to confirm what that buys. Meta-analyses tell the same modest story for body: lean mass up one to two kilograms, small-to-moderate strength gains, libido improved most in men with genuinely low levels. The honest frame: these effect sizes sit in the same ballpark as what progressive resistance training does for muscle and strength without a prescription, without lab monitoring, and without the fertility cost.

TRAVERSE: The Cardiovascular Question, Read Carefully

The trial everyone was waiting for arrived in 2023: TRAVERSE randomized 5,246 men aged forty-five to eighty with hypogonadism and cardiovascular risk factors to testosterone gel or placebo for roughly two years. The primary result — major cardiac events were non-inferior to placebo — is genuine, useful reassurance, and it has an honest ceiling: two years is not a lifetime, and the secondary signals all leaned one direction. More pulmonary embolism in the testosterone arm (0.9% versus 0.5%), more atrial fibrillation (3.5% versus 2.4%), more acute kidney injury (2.3% versus 1.5%) — each absolute difference small, each direction noteworthy. Prostate cancer, unexpectedly, appeared numerically less often in the testosterone arm, which the authors themselves cautioned not to over-read. The defensible summary: for older hypogonadal men, short-term cardiovascular safety is now better documented than for almost any other hormone therapy; long-term safety remains an open question, and the full picture of male cardiovascular risk has its own topic in this series.

Who TRT Is For — and Who It Is Not

The evidence supports treatment for clinical hypogonadism — the man with Klinefelter syndrome, pituitary disease, chemotherapy- or radiation-induced failure, testicular injury, or confirmed age-related hypogonadism with symptoms and two low morning measurements. That is clinician territory, end of sentence. The evidence does not support treatment for men with normal levels chasing "optimization," "longevity," or a subjective edge: no randomized trial demonstrates a benefit in that population, and the risks do not shrink to zero just because a clinic prints a normal range. Testosterone is prescription medicine — a controlled substance in many countries — precisely because suppressing the body's own production while thickening the blood is not a lifestyle choice. If a clinic's business model is selling normal-range men testosterone, the clinic is the red flag.

The Risks, Counted

Every risk below is manageable under monitoring and worth knowing before the first dose — they are the routine cost of a working prescription, not scare copy.

Before Testosterone: The Reversible Causes

For most men with a low-ish number and vague symptoms, the highest-value move is unglamorous: fix the things that are pushing the number down, then retest. A meta-analysis of the weight-loss evidence found that shedding roughly nine kilograms was associated with a testosterone rise of two to three nmol/L — the same order of magnitude as what some men get from a prescription, achieved by the weight-loss protocol instead of a pharmacy. Chronic sleep debt and untreated apnea depress the axis; heavy alcohol use suppresses the cells that make the hormone; opioids and glucocorticoids are notorious suppressors; and prolonged undereating tells the reproductive system the environment is hostile. The honest sequence is: sleep, weight, alcohol, and medication review first — then two morning lab draws — then, and only then, a conversation about whether the end of the flowchart (a prescription) is the right door.

Go Deeper: Subtopics

• 🔎 The age-related decline curve — what "normal" testosterone does across decades, and the wide individual range. Read it →
• 🔎 The symptom vs number question — when low-T symptoms matter more than the lab value. Read it →
• 🔎 The TRT trials — the TRAVERSE trial and friends: what testosterone therapy demonstrably does and doesn't. Read it →
• 🔎 TRT risks, honestly — cardiovascular signals, fertility suppression, and the monitoring requirements (⚠️). Read it →
• 🔎 Raising T without prescriptions — sleep, body fat, training, alcohol: the lifestyle levers ranked. Read it →

Related Topics